Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Materials and methods for treating viral infections with a cysteamine compound

A virus infection, cysteamine technology, applied in the treatment of virus-related symptoms, infecting animals with I-V viruses, preventing or delaying the occurrence of virus-related complications, can solve side effects, harmful host cell DNA replication, decreased therapeutic efficacy, etc. question

Inactive Publication Date: 2009-01-07
OMEGA BIOPHARMA H K
View PDF13 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these treatments have significant side effects as they are detrimental to host cell DNA replication or are only effective in limited viral infections
In addition, as shown above, viruses are known to be able to develop resistance to treatment, leading to a progressive decline in treatment efficacy
[0016] So far, no cysteamine compounds have been reported for the treatment of viral infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Materials and methods for treating viral infections with a cysteamine compound
  • Materials and methods for treating viral infections with a cysteamine compound
  • Materials and methods for treating viral infections with a cysteamine compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1 - Treatment of Influenza-Related Symptoms

[0070] A man with influenza virus infection who presented with symptoms associated with influenza infection (runny nose, fever, tiredness) was initially treated with over-the-counter nasal decongestants and mucolytics. Within 24 hours, the over-the-counter drug is not effective in treating flu-related symptoms.

[0071] After over-the-counter medications proved ineffective, the subject was orally administered cysteamine hydrochloride at a dose of approximately 700 mg. Within 24 hours, symptoms associated with influenza infection had disappeared. The subject displays a general sense of well-being.

Embodiment 2

[0072] Example 2-Studies on the Antiviral Activity of Cysteamine on H5N1 Avian Influenza Virus: Using Phosphoric Acid In vitro and in vivo studies of oseltamivir as a control

[0073] According to one embodiment of the present invention, cysteamine exhibits antiviral activity against H5N1 avian influenza virus. The subject-matter of the invention is particularly advantageous due to the unexpected results with avian influenza viruses. For example, as described below, cysteamine was particularly effective in the treatment of H5N1 avian influenza virus, even more effective than the registered anti-avian influenza drug oseltamivir phosphate (whose generic name is Tamiflu (TAMIFLU )) Much better.

[0074] Materials and methods

[0075] Cysteamine (hereinafter referred to as "TG21", containing 99% cysteamine) was provided by Omega Bio-Pharma (H.K.) Limited. Embryo eggs from specific pathogen-free (SPF) hens (Beijing, China) were used in this experiment. The CV strain of...

Embodiment 3

[0105] Antiviral activity of embodiment 3-cysteamine against H5N1 type avian influenza virus in mice Materials and methods

[0106] Cysteamine (hereinafter referred to as "TG21", containing 99% cysteamine) was provided by Omega Bio-Pharma (H.K.) Limited. H5N1 avian influenza virus WV strain was isolated from infected chickens. As described here, using Tamiflu (Shanghai, China, Roche (China) Co., Ltd.).

[0107] Evaluation of the 50% lethal dose (mLD50) of H5N1 avian influenza virus in mice

[0108] The preservation solution of H5N1 avian influenza (WV strain) was firstly diluted 1:5 with PBS, and then serially diluted by four times to obtain 5 dilutions (1:5 to 1:1280). Six- to eight-week-old female mice were anesthetized by intramuscular injection of 100 μL of 1% barbital sodium, and then the mice were inoculated by dripping 50 μL of diluted H5N1 avian influenza virus WV strain into the nasal cavity of each mouse (n=each diluted 10 mice). Animals were monitored da...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The subject invention provides materials and methods for treating various health conditions, including the prevention and / or treatment of a viral infection. In a preferred embodiment, a cysteamine compound is administered to a subject to treat an influenza virus infection. More preferably, a cysteamine compound is administered to a subject to treat influenza A, influenza B, influenza C virus infections, including avian influenza virus subtypes (such as H5N1 avian influenza virus).

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application Serial Nos. 60 / 740,584 (filed November 28, 2005), Serial No. 60 / 810,773 (filed June 2, 2006), Serial No. 60 / 818,885 (filed July 6, 2006), and Serial No. 60 / 847,020 (filed September 25, 2006), all of which are hereby incorporated by reference in their entirety, including any drawings and / or tables therein. Background technique [0003] A virus is a small parasite consisting of nucleic acid (RNA or DNA) enclosed in a protein coat. Viruses can only replicate by infecting a susceptible host cell and directing the host cell system to produce more virus. Glycoproteins (located in the protein capsid) mediate viral attachment and entry into susceptible host cells. [0004] Most viruses are divided into broad groups based on the type of nucleic acid formed during replication and the pathway by which mRNA is produced. Typically, viruses use RNA or DNA as their genetic materia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/145A61P31/12A61P31/16
CPCY02A50/30
Inventor 梁皓仪池豪胥清富陈彪
Owner OMEGA BIOPHARMA H K
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com